

TOWARDS A GLOBAL SCHIZOPHRENIA RESEARCH STRATEGY



Carta de Francesc Oliva II (1658) - Museu Marítim de Barcelona

Annual Report 2007

Català Español **English**

INDEX

PRESENTATION	3
RESEARCH INTERNATIONALISATION	4
• Extract from our Bibliometric Study (1999-2004)	4
• CIBER in Mental Health (Spain)	19
• Researchers in Europe and Israel	19
THE BOARD	20
• Modifications	20
ACTIVITIES, PROJECTS AND SERVICES	21
ONGOING PROJECTS	
• SENYFoundation 2005-2007	
II Open Call for Research Project Proposals in Schizophrenia	21
• SENYFoundation 2007-2011	
III Call for Coordinated Projects in Schizophrenia Research	23
COMMUNICATIONS AND DISSEMINATION	
• Archive Centre	24
• SENYFundació Web Page	27
• Dissemination of Courses and grants	27
• Presence of SENYFoundation in public acts	27
ECONOMIC RESOURCES, SOURCE OF RESEARCH FUNDS	29
• Family and friends	29
• Companies and corporations - CSR	29
SENYFOUNDATION COLLABORATION WITH OTHER ORGANIZATIONS	30

The Private **SENYFoundation** a non-profit organisation created in 1996 in order to promote research into schizophrenia and chronic mental illness. is registered in the Fundacions de la Generalitat de Catalunya and classified as a charitable foundation which focuses on assistance and science according to the resolution of July 10th, 1996. Registration number 998.

Anyone interested in receiving copies of this document may contact:
SENY Fundació Privada • Diputació, 238 àtic. 7 • 08007 Barcelona • Tel: 93 302 30 10
seny@senyfundacio.org • <http://www.senyfundacio.org>

Edition: **SENYFoundation** • Design: Jordi Sans • Translation and editing: **SENYFoundation** • Printing: **SENYFoundation**

PRESENTATION

It is over a decade since the **SENYFoundation** was set up. Now that the initial contacts necessary to ensure its future have been made, we will try to outline the guidelines which we believe should govern its activities.

As indicated in recent announcements, our activity will focus on promoting research into serious mental illnesses, mainly schizophrenia.

A brief history.

Engaging in any sort of project requires the necessary funding to carry it out. **SENYFoundation**, with its originally modest funds, first organised a contest, mainly intended for young researchers.

This contest had a double purpose: firstly, to award those projects that encouraged future research into schizophrenia in our country, and secondly, to begin to motivate our mental-health researchers while preparing the ground for a new, larger contest: the "Marató de TV3" telethon. This telethon consists of a public and private partnership that is committed to raising funds each year to combat a particular disease. To this end, on January 20, 1999, the **SENYFoundation** sent a proposal to "La Marató de TV3" requesting that they dedicate a telethon to schizophrenia and serious mental disorders.

Such an edition of "La Marató de TV3" was organised in 2000 and was a notable success, both in terms of the quality of the research projects presented, and in terms of educating the public against the social stigma that mental disorder so unfairly generates.

Funding and continuity.

As has been pointed out on many occasions, good research requires, among other things, funding and continuity.

With these objectives in mind, **SENYFoundation** raised the necessary funds to organise two new contests: one in 2005, which was won by the project "Genetics and neuroimaging markers of schizophrenia", led by Prof B. Crespo-Facorro of the Hospital Universitario Marqués de Valdecilla in Santander, and another in 2007 in which the winning project was "Monoaminergic neurotransmission in prefrontal cortex: Target for augmentation strategies in schizophrenia" with Dr F. Artigas of the Institut d'Investigacions Biomèdiques de Barcelona, CSIC-IDIBAPS as main researcher. Both projects are currently ongoing, with satisfactory preliminary results.

Finally, continuity and further necessary research funding have been secured recently thanks to "La

Marató de TV3 2008", entitled "Serious Mental Disorders". This followed an application which was led, along with other institutions, by our own foundation.

Research Internationalisation.

The level of research into mental illness in Spain, and specifically in Catalonia, has increased to a degree that would hardly have been credible only a decade ago. Despite this, research into mental illness in our country must overcome two significant obstacles that prevent it from reaching the level of the leading European countries in this field. The first obstacle is a lack of links with researchers in other countries. This follows largely from another instrumental obstacle; our limitations in terms of the English language, the current lingua franca of knowledge.

A proposal.

As previously mentioned, commitment to a further edition of "La Marató de TV3" has been obtained under the title "Serious Mental Disorders."

The average funding raised in recent editions has been around 7 million euros. We believe that this magnificent opportunity should be used to promote the international links that we alluded to above. The way to achieve this is by giving a certain priority to those projects that are presented in collaboration or coordination with eminent researchers and/or foreign institutions in the field.

Typically, 4 or 5 years after funds are awarded to a project; there is a public presentation of the work to expert interested parties. We believe this would be a perfect opportunity to have these presentations coincide with an **international congress** devoted to the subject of the corresponding telethon, with leading European international experts invited to Spain to speak on the material in question. This would increase the international links we are seeking, as well as acting as a forum for attracting new talent.

Jordi Masià Mas-Bagà
President
SENYFoundation



RESEARCH INTERNATIONALISATION

EXTRACT FROM OUR BIBLIOMETRIC STUDY (1999-2004)


LIST OF RESEARCH GROUPS AND MAIN FEATURES

Group	Group Leader	Docs in the group	% of Docs with the group	National Researchers	International Researchers	National Centers	International Centers
1	J. Bobes García	31	65	13	0	7	0
2	S. Lemos Giráldez	14	93	12	0	2	0
3	PA. Sáiz	4	100	5	0	3	0
4	C. Iglesias García	4	100	2	0	3	0
5	JL. Vázquez-Barquero	32	81	7	16	2	12
6	B. Crespo Facorro	5	100	1	6	1	4
7	I. Lastra Martínez	6	83	3	1	3	1
8	A. Espina Eizaguirre	7	100	6	0	1	0
9	MJ. Cuesta Zorita	30	83	7	0	2	0
10	I. Mata Pastor	8	75	3	5	3	2
11	JM. Haro Abad	24	46	9	3	4	4
12	M. Bernardo Arroyo	28	68	19	0	5	0
13	E. Álvarez Martínez	16	44	7	0	5	0
14	G. Gastó Ferrer	11	64	7	0	5	0
15	C. Junqué Paja	9	67	5	0	3	0
16	JE. Obiols	12	83	4	0	2	0
17	L. Fañanás Saura	9	100	5	7	1	8
18	L. San Molina	9	100	9	0	3	0
19	E. Vilella	7	71	7	0	3	0
20	S. Ferré	5	100	5	7	1	4
21	JL. Tizón García	5	100	8	0	3	0
22	N. Durany	4	100	1	10	1	8
23	F. Artigas	3	100	4	0	2	0
24	M. Sunyer	2	100	2	0	2	0
25	A. Palmer	2	100	3	0	1	0
26	C. Leal Cercós	18	89	12	0	8	0
27	J. Sanjuán Arias	23	35	10	0	13	0
28	I. Montero	5	100	8	0	3	0
29	A. Pedrós Roselló y A. Tomás Pérez	4	100 75	2	0	2	0
30	A. Javaloyes	2	100	1	3	1	2
31	EJ. Aguilar García-Iturrrospe	3	100	4	0	4	0
32	J. Giner Ubago	8	63	6	0	5	0
33	F. Torres González	16	63	8	1	5	1
34	J. De León	6	67	2	2	1	2
35	S. Perona Garcelán	10	90	8	0	1	0
36	L. Gonzalo de la Casa	5	100	1	1	1	1
37	R. Jiménez	2	100	2	0	2	0
38	D. Noval	2	100	2	0	1	0
39	B. López Luengo	8	88	3	0	4	0
40	LJ. Fuentes	6	67	4	2	2	2
41	A. Llerena	4	100	4	0	2	2
42	JC. Gómez Pérez	28	57	9	1	9	2
43	V. Molina Rodríguez	19	79	17	3	8	1
44	M. González de Chávez	9	100	6	0	4	4
45	C. Arango López	8	100	1	1	1	0
46	FJ. Quintero Gutiérrez	6	83	5	0	4	2
47	E. Cuenca	5	80	3	1	1	0
48	A. Viserda Antoraz	4	100	4	0	1	1
49	JM. López-Frutos	3	100	3	0	1	0
50	T. Ortiz Alonso	3	100	3	0	2	0
51	MA. Gorriti, M. Navarro y F. Rodríguez de Fonseca	2	100	3	0	2	0
52	N. Tur Salamanca	3	67	2	0	1	0
53	LM. García-Segura	3	100	2	1	2	1
54	RM. Sanguino Andrés	5	100	4	0	1	0
55	JJ. Padín	3	67	3	0	3	0
56	LJ. Fernández y B. Yañiz Igal	2	100	2	0	2	0


They have collaborated with researchers and/or foreign institutions

Group 1, with the participation of the Universidad de Oviedo, Hospital de Cruces from Baracaldo, Hospital Santiago Apóstol from Vitoria, Pfizer Laboratories, CRO Biométrica (Clinical Research Organization), Janssen Research Foundation Laboratories from Madrid and the Universidad del País Vasco. Group led by Julio Bobes García and comprised of the following researchers : Miguel Gutiérrez Fraile, Javier Rejas, Ana González Pinto, Marisa L. Herráiz, Gonzalo Hernández, Juan Luis Figuerido Poulain, M.P. González, Margarida García García, M.P. García-Portilla, R. Segarra Echevarría, F. Rico Villademoros and F. Mosquera. Some of the research has been developed in the national networks EUROPA and EIRE. There are 2 other groups very closely related to this one, one led by P.A. Saiz (group 3) and another by Enrique Álvarez Martínez (group 13).

Group 1 | Num. Docs 31




Group 2 | Num. Docs: 14




Group 2, with the participation of the Department of Psychology from the Universidad de Oviedo and Hospital Sierrallana from Torrelavega. Group led by Serafín Lemos Giráldez and made up of Oscar Vallina Fernández, José Luis Besteiro González, Ana M^a López Rodrigo, Ana M^a Gutiérrez Pérez, M. Mercedes Paino Piñero, Pedro C. Martínez Suárez, Mercedes Inda Caro, Ana García Saiz, Aurora Otero García and Marta Alonso Sánchez.

Group 3 | Num. Docs: 4




Group 4 | Num. Docs: 4




Group 3, with the participation of the Universidad de Oviedo together with the Hospital Universitario Central de Asturias and the SESPA (Servicio de Salud del Principado de Asturias [Principality of Asturias Health Service]). Group led by P.A. Saiz and made up of B. Morales, Victoria Álvarez, E. Coto and J.M. Fernández. This group is very closely related to group 1 led by Julio Bobes García.

Group 4, with the participation of Hospital Valle del Nalón from Langreo, Hospital Adaro from Langreo and SESPA (Servicio de Salud del Principado de Asturias). Made up of C. Iglesias García (leader) and S. Santamarina Montilla.

Group 5, with the participation of Universidad de Cantabria and Hospital Universitario Marqués de Valdecilla. Led by José Luis Vázquez Barquero and made up of the following researchers: Andrés Herrán, Luis Gaité, M^a Teresa García Unzueta, José Antonio Amado Señarís, Concepción Álvarez and Elena Vázquez Bourgon. This group has high international visibility and receives collaboration from 16 foreign researchers. The collaborations come from: Institute of Psychiatry from London, London School of Economics and Political Science, London School of Hygiene and Tropical Medicine, University of Amsterdam, Netherlands Institute of Mental Health and Addictions in Utrecht (Netherlands), Università di Verona (Italy), Copenhagen University Hospital, Hvidovre Hospital in Copenhagen, Psychiatric Center North in Naestved (Denmark), University of Leipzig (Germany), University of Ulm (Germany), Global Program on Evidence for Health Policy World Health Organization (Geneva, Switzerland). Most of its research has been developed within the international network EPSILON.




Group 6, with the further participation of Hospital Universitario Marqués de Valdecilla, made up of just one Spanish author, Benedicto Crespo Facorro, in collaboration with 6 foreign researchers. The collaborations come from: University of Iowa Hospital and Clinic (USA), MIND Institute of Albuquerque (USA), University of New Mexico (USA) and Seoul National University (South Korea).




Group 7, with the participation of the Centro Psiquiátrico Benito Menni of Santander, Hospital Universitario Marqués de Valdecilla and Universidad de Cantabria. The group is led by Ismael Lastra Martínez and is made up of the researchers Sara Herrera Castanedo and M^a Jesús Cuesta Nuñez. This is a small group that has an international collaboration with the University of Manchester (United Kingdom) and which is very closely related to group 5, led by José Luis Vázquez Barquero.

Group 8, with the participation of Universidad del País Vasco. The group is led by Alberto Espina Eizaguirre and is made up of: Begoña Pumar González, Pilar González Peláez, Ana Eyerbe Berandiarán, Asunción Santos Morocoa and Enrique García Martín.

Group 9, with the further participation of Hospital Universitario Virgen del Camino of Pamplona and Osakidetza (Basque Health Service). The group is led by Manuel Jesús Cuesta Zorita and also includes Víctor Peralta Martín, Amalia Zarzuela Ituarte, José Fermín Serrano, Jesús Alfredo Martínez Larrea, María Artamendi and Patxi Gil.




Group 10, with the participation of the Argibide Foundation of Navarra, Hospital Universitario Virgen del Camino of Pamplona and the Burlada Health Service (Navarre). The group is led by Ignacio Mata Pastor and includes M. Beperet Urmeneta and F. Pérez Nievas. This group enjoys international attention and collaborates with 5 foreign researchers. Collaborating with: the Institute of Psychiatry of London and the Withington Hospital of Manchester (United Kingdom). Some of the research has been developed within the national network PSICOST.




Group 11, with the participation of Hospital Sant Joan de Déu-SSM of Sant Boi del Llobregat and some of its various assistance services in the metropolitan area of Barcelona (Mental Health Center El Prat and Mental Health Center Cornellà) in collaboration with IMIM (Institut Municipal d'Investigació Mèdica [Municipal Institute of Medical Research], from Barcelona). The group is led by Josep M^o Haro Abad and is made up of the following researchers: Judith Usall Rodié, Susana Ochoa Güerre, M. Márquez, Susana Araya La Ribera, A. Gost, E. Busquets, Jaume Autonell Caldentey, Jordi Alonso and 3 foreign researchers. This group has international collaboration with Addensbrooke's Hospital of Cambridge, the University of Cambridge and the laboratories Eli Lilly of Surrey (United Kingdom) and of Indianapolis (USA). Most of its research has taken place within the national networks NEDES and PSICOST, and the international network SOHO.

Group 12, with the participation of Hospital Clínic of Barcelona, Universitat de Barcelona, IDIBAPS (Institute of Biomedical Research August Pi i Sunyer), Hospital Sant Pau i de la Santa Creu from Barcelona and Hospital de Mataró. The group is led by Miquel Bernardo Arroyo and is made up of the following researchers: Manel Salameo Baro, Rafael Penadés Rubio, Eduard Perallada Rodón, Francisco J. Lomeña Caballero, Teresa Boget Lluçia, Lorena Rami González, Ana M^a Catafau Alcàntara, Mireia Font, Javier Pavia, Fernando Gutiérrez, Rosa Catalán, Sílvia Cañizares Alejos, S. Catarineu, José Javier Mateos Fernández, Emilio Fernández Egea, Magdalena Castellví, Imma Baeza Pertegaz and M^a Jesús Portella Moll. There is another group which is very closely related to this one which is led by Carme Junqué Paja (group 15).

Group 13, with the participation of Hospital de Sant Pau i la Santa Creu of Barcelona, Universidad de Cádiz, Psychiatric Hospital of Madrid, Hospital Mútua de Terrassa and Hospital Fundació Jiménez Díaz from Madrid. The group is led by Enrique Álvarez Martínez and is made up of the researchers Juan Gibert Rahola, Fernando Cañas, Iluminada Corripio Collada, Víctor Pérez, José Luis Carrasco and Josep Gascón. Some of the research has taken place within the national network EUROPA. The group is very closely related to group 1, led by Julio Bobes García.




Group 14, with the participation of Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS (Institute of Biomedical Research August Pi i Sunyer), Stanley Research Center and Janssen Research Foundation laboratories from Madrid, this group is led by Cristóbal Gastó Ferrer and is made up of the following researchers: Eduard Vieta Pascual, Antonio Benabarre Hernández, María Reinares Gagnetten, Anabel Martínez Arán, Francesc Colom Victoriano and Antonio Fernández. Some of its research has taken place through the local networks EFESO and GSRAD.




Group 15, is a third group from Universitat de Barcelona, IDIBAPS (Institute of Biomedical Research August Pi i Sunyer) and Hospital Clínic de Barcelona, led by Carme Junqué Paja and made up of the following researchers: Pilar Salgado Pineda, Pere Vendrell, Mercedes Pérez Gómez and Núria Bargalló. This group works closely with researchers from Hospital Clínic de Barcelona, group 12, led by Miquel Bernardo Arroyo.

Group 16, with participation from 2 Catalan universities: Universitat Autònoma de Barcelona and Universitat de Girona. The group led by Jordi Obiols Llandrich and includes the following researchers: Neus Barrantes Vidal, Beatriz Caparrós Caparrós and Jordi Vicens Vilanova. This group works closely with the researchers from group 17 from Universitat de Barcelona, led by Lourdes Fañanás Saura, and therefore also enjoys international visibility.

Group 17 | Num. Docs: 9




Group 18 | Num. Docs: 9




Group 17, with the participation of researchers from Universitat de Barcelona. Led by Lourdes Fañanás Saura, it includes the following researchers: Araceli Rosa, Bárbara Arias, Sergi Papiol and B. Gutiérrez. This group enjoys significant international visibility thanks to its collaboration with researcher Jim Van Os (Transnational Limburg-Maastrich University and Institute of Psychiatry of London), who collaborates with researchers from Hôpital Pasteur from Nice (France), University of Hamburg (Germany), San Hans Hospital Roskilde (Dinamarca), Trafford General Hospital (Manchester, United Kingdom), Università de Milano (Italy) and University Hospital for Psychiatry (Vienna, Austria). This group works closely with researchers from other Catalan universities, such as those from group 16 led by Jordi Obiols Llandrich.

Group 18, with the participation of CASM Benito Menni from Sant Boi de Llobregat, the Ciutat Sanitaria i Universitaria de Bellvitge and the Hospital General de Granollers. The group is led by Lluís San Molina and includes the following researchers: Belén Arranz Martí, Nicolás Ramírez Nebreda, Salvador Sarró Maluquer, Rosa Mª Dueñas Herrero, Pilar Rosel Soria, José M. González Calvo, José Mª Sanchez and Mª Luisa Miralles.

Group 19 | Num. Docs: 7




Group 20 | Num. Docs: 5



Group 19, with the participation of Universitat Rovira i Virgili of Tarragona, Hospital Universitario Sant Joan de Reus and the Hospital Psiquiàtric Universitari Institut Pere Mata from Reus. This group is led by Elisabet Vilella and is made up of the following researchers: Antoni Labad Alquézar, Joaquín Valero Oyarzabal, Lourdes Martorell Bonet, Carmen Virgos, Lidia Figuera and Jorge Joven.

Group 20, with the participation of the Departament de Molecular Biology from Universitat de Barcelona and 4 foreign centers: Karolinska Institute (Sweden), National Institutes of Health (USA), Università di Modena (Italy) and Istituto Superiore di Sanita di Roma (Italy). The group is led by Sergi Ferré, who is affiliated with two foreign centers and includes: Meritxell Canals, Vicent Casadó, Carme Lluís, Francisco Ciruela and Rafael Franco. The group also includes 6 other foreign researchers.

Group 21 | Num. Docs: 5



Group 22 | Num. Docs: 4



Group 21, with the participation of USM Sant Martí-La Mina from Barcelona, the Municipal Health Institute of the City Hall of Barcelona and private offices from Barcelona. The group is led by Jorge Luis Tizón García and is formed by: Jordi Artigue Gómez, F. Pareja, Belén Parra Ramajo, Marta Goma Llairó, J. Fernando, M. Sorribes and C. Pérez.

Group 22, in which only one Spanish researcher participates, Núria Durany from the Universitat Internacional de Catalunya who leads the group. The group includes 10 foreign researchers from the following centers: University of Würzburg (Germany), State Hospital (Austria), University of Heidelberg (Germany), Ludwig Boltzmann Institute (Austria), University of Munster (Germany), Geriatric Center Wienerwald (Austria), AKH (Allgemeines Krankenhaus) (Austria) and University of Innsbruck (Austria).

Group 23 | Num. Docs: 3



Group 24 | Num. Docs: 2




Group 23, with the participation of IIBB (Institute of Biomedical Research of Barcelona)–CSIC and IDIBAPS (Institute of Biomedical Research August Pi i Sunyer). The group is led by Francesc Artigas and includes M^a Victoria Puig, Albert Adell and Pau Celada.

Group 24, with the participation of the Centres Assistencials Dr. Emili Mira from Santa Coloma de Gramanet and from Universitat Ram3n Llull. Grupo is comprised of: Miquel Sunyer (leader) and L. Rico Bodi.

Group 25 | Num. Docs: 2




Group 26 | Num. Docs: 18



Group 25, with the participation of the Universitat de les Illes Balears. This group is led by A. Palmer Pol and includes Beatriz Terrassa Blázquez and Francisco J. Pérez Pareja.

Group 26, with the participation of the following Valencian centers: Universidad de Valencia, Hospital Clínico Universitario de Valencia, Hospital Universitario la Fe, Hospital Doctor Peset, Hospital de Sagunto, CS Paterna, CSM Malvarrosa and Agencia Valenciana de la Salud. This group is led by Carmen Leal Cerc3s and is made up of the following researchers: Manuel G3mez Beneyto, Rafael Tabar3s Seisdedos, Gabriel Selva Vera, Jos3 Salazar Fraile, Vicente Balanz3 Mart3nez, J.S. Arias, Yolanda Pallard3, Concepci3 Vilela Soler, Francisco Ballester S3nchez, Rosa C3zar Santiago and Miguel Vallet. This group is closely related to group 27, led by Julio Sanju3n Arias.

Group 27 | Num. Docs: 23




Group 28 | Num. Docs: 5




Group 27, in which several Spanish centers participate: Hospital Basurto from Bilbao, Complejo Hospitalario Xeral-Ciés from Vigo, Universidad de Valencia, Universidad de Oviedo, Hospital Clínico Universitario from Salamanca, Hospital Clínico Universitario from Valencia, Complejo Hospitalario Carlos Haya from Málaga, IMAS (Municipal Institute of Health Assistance) from Barcelona, Universidad del País Vasco, Universidad de Salamanca, Osakidetza (Basque Health Service), Portugalete Mental Health center from Vizcaya and the mental health institute Alcobendas from Madrid. This group is led by Julio Sanjuán Arias and is made up of the following researchers formado por los investigadores: Miguel Ángel González Torres, José Manuel Olivares, M. Bousuño García, Aránzazu Fernández Rivas, José C. González, Fermín Mayoral, Angel Luis Montejo, F. Ferre Navarrete and Salvador Ros. This group is closely related to group 26, led by Carmen Leal Cercós.

Group 28, with the participation of Universidad de Valencia, Universidad Miguel Hernández of Elche and the Asociación AFEM from Valencia. This group is led by Isabel Montero and is made up of the following researchers: Ana P. Asencio, Isabel Ruiz Pérez, Ildefonso Hernández, María Lacruz, Ma José Masanet, Francisco Bellver and Mercedes Iborra.

Group 29 | Num. Docs: 4



Group 30 | Num. Docs: 2




Group 29, with the participation of Hospital Lluís Alcanyis and USM from Xàtiva, Valencia. This group is made up of the researchers A. Pedrós Roselló and A. Tomás Pérez, both of whom act in the in the capacity of leaders.

Group 30, with the participation of Hospital Provincial from Alicante, this group has only one Spanish researcher, Auxi Javaloyes who works together with 3 foreign researcher from the Institute of Health Sciences at Oxford and Warneford Hospital also in Oxford (United Kingdom).

Group 31 | Num. Docs: 3




Group 32 | Num. Docs: 8




Group 31, with the participation of Universidad de La Laguna from Santa Cruz de Tenerife, the Hospital Universitario of Canarias, Hospital de Sagunto from Valencia and Hospital de la Ribera Alcira from Valencia. This group is led by E.J. Aguilar García Itulturrospe and includes: R. García Marco, M.R. Cejas Méndez and M.L. Villaverde Ruiz.

Group 32, with the participation of the Universidad de Sevilla, Universidad Autónoma de Madrid, Hospital Universitario Puerta del Hierro from Madrid, Universidad de Valencia and Clínica Universitaria de Navarra. This group is led by: José Giner Ubago and includes the following researchers: M.D. Mojarro Práxedes, M. Camacho, Salvador Cervera Enguix, E. Ibáñez and Enrique Baca Baldomero.



Group 33, with the participation of Universidad de Granada, Hospital Clínico de Granada, Hospital Psiquiátrico Universitario San Cecilio de Granada, the Área de Rehabilitación de Granada and Universidad de Jaén. This group is led by Francisco Torres González and includes the following researchers: Juan F. Godoy García, Berta Moreno Küstner, José Antonio Muela Martínez, Guadalupe Martínez Montes, Carmen Rosales Varo, J.F. Jiménez Estévez and J. Luna del Castillo. The group collaborates with a foreign researcher from the University of Heidelberg (Germany).


Group 34, with the participation of a second group from Universidad de Granada and these foreign institutions: Eastern State Hospital of Lexington (USA) and Universidad Nacional de Medellín (Colombia). The group is led by José de León, a researcher associated with a foreign institution, and includes the following researchers: Manuel Gurpegui, José M. Martínez Ortega in collaboration with another foreign researcher.



Group 35, with the participation of the Mental Health Rehabilitation Unit of the Virgen del Rocío University Hospital Complex of Seville. This group is led by Salvador Perona Garacelán and formed by Carlos Cuevas Yust, José Manuel Ramos León, Agustina Hervás de la Torre, Remedios Dorado García, Manuel Jesús Martínez López, Margarita Laviana Cuetos and Emilia Navarrón Cuevas.

Group 36, with the participation of Universidad de Sevilla. The group is made up of only one Spanish researcher: Luis Gonzalo de la Casa who collaborates with a foreign researcher from Tel Aviv University (Israel).

Group 37 | Num. Docs: 2




Group 38 | Num. Docs: 2




Group 37, with the participation of the University Hospital Complex Virgen del Rocío and Hospital Virgen Macarena from Seville. The group consists of Rosa Jiménez García-Bóveda (leader) and Antonio J. Vázquez Morejón.

Group 38, with the participation of Hospital Universitario de Valme, Seville. It is made up of D. Noval (leader) and A. Moriño.

Group 39 | Num. Docs: 8




Group 40 | Num. Docs: 6




Group 39, with the participation of Universidad de Jaén, Universidad Complutense de Madrid, the Centro de Estudios Universitarios CEU from Madrid and Hospital Beata M^o Ana from Madrid. The group is led by Beatriz López Luengo and formed by Carmelo Vázquez Valverde and Alejandro Florit Robles.

Group 40, with the participation of Universidad de Almería and the Torrecárdenas Hospital Complex of Almería. Led by Luis J. Fuentes. This group is made up of the following researchers: Encarnación Santiago, Roberto Álvarez and Ana B. Vivas. The group enjoys international visibility as it collaborates with two foreign researchers. It collaborates with the Institut National de la Santé et de la Recherche Médicale and the Hôpital Civil de Strasbourg (France).



Group 41, with the participation of Universidad de Extremadura and Hospital Psiquiátrico Provincial ADA from Badajoz. Led by Adrián Llerena (Universidad de Extremadura and Beira Interior University, Portugal) and made up by Alfredo De la Rubia, Roland Berecz (Universidad de Extremadura and University of Debrecen, Hungary) and Pedro Dorado.


Group 42, in which basically researchers from the Eli Lilly labs from Madrid participate. Led by: Juan Carlos Gómez Pérez and consisting in: José Antonio Sacristán, Luis Prieto, Antonio Ciudad (who had worked at the Centro Residencial y Rehabilitador San Rafael of Lugo), Juan A. Ormaechea Beldarían (who had worked at the Hospital Universitario Gregorio Marañón and the Benito Menni Psychiatric Center of Santander), Tatiana Dilla and Carmen López-Carrero García with different researchers from Spanish centers: J.M. Montes Rodríguez from Universidad de Alcalá and University Hospital Príncipe de Asturias, Xavier Badia from the Catalan Health Institute and the Hospital de Sant Pau i la Santa Creu of Barcelona; and a researcher from Eli Lilly, Surrey (United Kingdom). Most of their research has developed within the national networks EFESO, EUROPA and HGBG and the international network SOHO.



Group 43, with the participation of researchers from Hospital 12 de Octubre of Madrid, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Universidad Politécnica de Madrid, Centro para la Evolución y el Comportamiento Humanos (UCM-ISCIH), Hospital Clínico Universitario de Salamanca, Universidad de Córdoba and Hospital Reina Sofía of Córdoba. The group is led by Vicente Molina Rodríguez and is made up of: Tomás Palomo Álvarez, Manuel Desco, Javier Sanz, Santiago Reig, Manuel Martín-Loeches Garrido, Juan D. Gispert, Javier Pascau, Fernando Sarramea, Francisco Muñoz, Carlos Benito, Juan Francisco Artaloytia Usobiaga, Rogelio Luque Luque, José A. Hinojosa, Pilar Casado, Andrés Santos and María Aragüés, as well as 3 foreign researchers from East Tennessee State University (USA), Queen's University (Canada), University of Goteborg (Sweden) and University of Orebro (Sweden).

Group 44, with the participation of researchers from Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Hospital Psiquiátrico de Madrid and the Mental Health Service Usera from Madrid. The group is led by Manuel González de Chávez Méndez and is made up of: Ignacio García Cabeza, Juan Carlos Fraile, Marta Gutiérrez Rodríguez, Marta Sanz Amador and Emilio Ignacio Sánchez Díaz. One of the studies was conducted through the national network EFESO.

Group 45 | Num. Docs: 8




Group 46 | Num. Docs: 6



Group 45, in which there is only one Spanish researcher, Celso Arango López from Hospital General Universitario Gregorio Marañón and from the University of Maryland (USA) in collaboration with a foreign researcher from the Maryland Psychiatric Research Center (USA). This group maintains a significant relationship with groups 43 and 44, led by Vicente Molina Rodríguez and Manuel González de Chávez Méndez.

Group 46, with the participation of Hospital Ramón y Cajal from Madrid, Hospital Fundación Jiménez Díaz from Madrid, Universidad Autónoma de Madrid and Universidad de Alcalá. The group is led by F.J. Quintero Gutiérrez del Álamo and is made up of: C. Riza Bermuda-Soriano, Alfonso Chinchilla Moreno, J. Correas Lauffer and R. Puente García.

Group 47 | Num. Docs: 5




Group 48 | Num. Docs: 4



Group 47, with the participation of universidad de Alcalá, led by Eduardo Cuenca and made up by: Francisco López Muñoz and Cecilio Álamo, and a foreign researcher from South Dakota University (EEUU).

Group 48, with the participation of Hospital Universitario de la Princesa from Madrid. The group is led by A. Virseda Antoranz and is formed by: María Portela Vicente, L. Gayubo Moreo and A. García Recio.

Group 49 | Num. Docs: 3




Group 50 | Num. Docs: 3




Group 49, with the participation of the Psychology Department of Universidad Autónoma de Madrid. The group is led by José M^o López Frutos and is formed by: José M^o Ruiz Vargas and Rosalía Hillers Rodríguez.

Group 50, with the participation of Universidad Complutense de Madrid and the Centro San Juan de Dios Ceimpozuelos from Madrid. The group is led by Tomás Ortiz Alonso and comprises: J.M. Manzano Callejero and E. Capdevila.

Group 51 | Num. Docs: 2




Group 52 | Num. Docs: 3



Group 51, with the participation of Universidad Complutense de Madrid and Hospital 12 de Octubre from Madrid. The group is made up by: Miguel Ángel Gorriti, Miguel Navarro and Fernando Rodríguez de Fonseca, all three of whom act as leaders.

Group 52, with the participation of Mental Health Services Psychiatric Institute José Germain from Madrid. The group comprises N. Tur Salamanca (leader) and O. Jiménez Suárez.

Group 53 | Num. Docs: 3




Group 54 | Num. Docs: 5




Group 53, with the participation of Instituto Cajal-CSIC from Madrid and Universidad Complutense de Madrid. The group is made up by Luis Miguel García Segura (leader) and Iñigo Azcoitia, in collaboration with a foreign researcher at Loyola University (USA).

Group 54, with the participation of the Complejo Hospitalario San Luis from Palencia, led by: R.M. Sanguino Andrés and made up by: Emilio González Pablos, F. Alonso del Teso and Luis Mínguez Martín.

Group 55 | Num. Docs: 3



Group 56 | Num. Docs: 2



Group 55, with the participation of Hospital Fundación Alcorcón from Madrid, the Centro Regional de Salud Pública from Talavera de la Reina and private offices from Lugo. The group is led by J.J. Padín Calo and is made up by: F. Arias Horcajada and S. Sánchez Romero.

Group 56, with the participation of Grupo Médico Asociado from Tudela and the Tudela Health Center (Navarre). The group comprises Luis J. Fernández Rodríguez and Blanca Yáñez Igal, the two of whom share their capacity as leaders.

CIBER IN MENTAL HEALTH (SPAIN)

Recently the CIBER in Mental Health group was formalised. CIBER (Centro de Investigación Biomédica en Red) is a research organism enjoying its own legal status that is committed to monographic research on, widely defined, a particular pathology or health problem; in this case, Mental Health. It is made up of research groups that belong to different administrations, institutes and autonomous communities from the private or public sector. Research areas and objectives are

centered on mental health, and coordinate with other groups in order to achieve scientific objectives which could not be fully dealt with in a narrower research context. The CIBER in Mental Health exists alongside 8 other CIBERs that exist in various areas of biomedical research in our country. These initiatives are financed by the Instituto de Salud Carlos III (www.isciii.es)

The Mental Health CIBER is constituted by:

Celso Arango López. Scientific Director	Hospital General Universitario Gregorio Marañón
Julio Bobes	Universidad de Oviedo
Jorge Cervilla	Universidad de Granada
Manuel Desco	Hospital General Universitario Gregorio Marañón
Javier Garzón	Instituto Cajal – CSIC
Juan José López-Ibor	Universidad Complutense de Madrid
Juan Carlos Leza	Universidad Complutense de Madrid
Juan Antonio Mico	Universidad de Cádiz
Edith Pomarol-Clotet	Benito Menni Complejo Asistencial en Salud Mental
Francesc Artigas Pérez	Institut d'Investigacions Biomèdiques de Barcelona, CSIC-IDIBAPS
José Luis Ayuso Mateos	Universidad Autónoma de Madrid
Miguel Bernardo Arroyo	Hospital Clínic de Barcelona
Lourdes Fañanás Saura	Universidad de Barcelona
Ana González Pinto	Hospital Santiago de Vitoria
José María Haro Abad	Sant Joan de Déu, Serveis de Salut Mental
Antonio Lobo Satué	Universidad de Zaragoza
Rafael Tabarés Seisdedos	Universitat de València
Javier Meana Martínez	Universidad del País Vasco
Tomás Palomo Álvarez	Universidad Complutense de Madrid
Ángel Pazos Álvarez	Universidad de Cantabria
Victor Pérez Sola	Hospital de la Santa Creu i Sant Pau
Jerónimo Sáiz Ruiz	Hospital Universitario Ramón y Cajal
Julio Sanjuán Arias	Universitat de València
Julio Vallejo Ruiloba	Hospital Universitario de Bellvitge
Eduard Vieta Pascual	Hospital Clínic de Barcelona

SOME OUTSTANDING RESEARCHERS IN EUROPE AND ISRAEL

Dr Sabine Bahn	Cambridge University, U.K.
Dr Peter Jones	Cambridge University, U.K.
Dr Paul Harrison	Oxford University, U.K.
Dr Preban Mortensen	University of Aarhus, Denmark
Dr William Deakin	University of Manchester, U.K.
Dr Eve Johnstone	University of Edinburgh, U.K.
Dr Robin Murray	Institute of Psychiatry, London, U.K.
Dr Robert Belmarker	University of Beersheva, Israel
Prof Jim van Os	Maastricht University, The Netherlands
Prof Uriel Heresco-Levi	Herzog Hospital, Israel



THE BOARD

SENYFoundation trust is comprised of the following members:

President:	Jordi Masià Mas-Bagà
Vice-president:	Francesc Enrich Muls
Members:	Imma Camp Vila Emili Cuatrecasas Figueras Pedro Fontana García Pedro Gallo de Puelles Ramon Guardans Vallès † Carlos Jané Camacho Joan Majó Cruzate Ernest Maragall Mira Joan Artur Margenat Padrós Pere Masià Figueras Casimiro Molins Ribot Antoni Negre Villavecchia Juan Rodés Teixidor Gerardo Salvador Coderch Juan Antonio Samaranch Torelló Antoni Sansalvadó Tribó Juan M. Torres Riera Antoni Vila Casas
Secretary:	Raimon Bergós Civit

MODIFICATIONS

The changes made to the Board and the internal organisation reflect the decision made by the Board Committee to concentrate our efforts on promoting schizophrenia research, and in particular involve the naming of Dr Juan Rodés Teixidor as Patron of our foundation. In addition, Dr Pedro Gallo de Puelles, who has carried out his management responsibilities for over three years with distinction, will continue to collaborate with us as Patron of **SENYFoundation**.

Finally, we record with deep regret the passing of our very dear founding Patron Mr Ramon Guardans Vallès.



ACTIVITIES, PROJECTS AND SERVICES

ONGOING PROJECTS

2005-2007 SENYFOUNDATION II OPEN CALL FOR RESEARCH PROJECT PROPOSALS IN SCHIZOPHRENIA

WINNING PROJECT

"Genetics and neuroimaging markers of schizophrenia", winning project, directed by Dr Benedicto Crespo-Facorro as main researcher (Hospital Universitario Marqués de Valdecilla, Santander), financed with 255.750 €.

GENERAL DEVELOPMENT OF THE PROGRAM

The monitoring of the third year of all patients included in the initial PAFIP program has practically concluded (PAFIP-I, from February 2001 to February 2005), as has the data collection regarding this period. We have had much coordination and discussion of results, including meetings with the London Institute of Psychiatry and the University of Yonsei, Seoul. These meetings have served to optimise the neuroimage protocol (DTI) and the databases and resulting genetic analysis.

UPDATING THE DATABASE

We have maintained the updating of the longitudinal databases by year relating to the evaluations of all patients included in our program up to September of 2006, making available for analysis all the definitive clinical (psychotic, affective and general psychopathology, initial monitoring of treatment, initial response to treatment, side effects and adherence), social (sociodemographic and epidemiological aspects and social, professional and family functioning) and cognitive data (applied neuropsychological battery) relative to the first year of treatment. This updating has allowed us to begin publishing the first longitudinal analyses of our study,

ORAL PRESENTATIONS

Roiz-Santiañez R et al. "Interleukin-1 receptor antagonist genotype and brain morphometry in first episode schizophrenia patients". Association of European Psychiatrists, Section of Neuroimaging. 4th Annual Meeting. Santander, Spain. May 2007

Roiz-Santiañez R et al. "Low-activity allele of catechol-o-methyltransferase (COMT-L) is associated with increased lateral ventricles in patients with first episode of schizophrenia". Association of European Psychiatrists, Section of Neuroimaging. 4th Annual Meeting. Santander, Spain. May 2007

Pelayo-Terán JM et al. "Caudate nucleus volume and its clinical correlations in first episode schizophrenia". The Organization for Human Brain Mapping 13th Annual. Chicago, USA. June 2007

Roiz-Santiañez R et al. "Cortical gyrification abnormalities in first episode schizophrenia". The Organization for Human Brain Mapping 13th Annual. Chicago, USA. June 2007

Vázquez-Bourgon J et al. "Association between serotonergic polymorphism to long-term response to antipsychotics in first episode psychosis". World Congress on Psychiatric Genetics XV. New York City, USA. 2007

Roiz-Santiañez R et al. "Low-activity allele of catechol-o-methyltransferase (COMT-L) is associated with increased lateral ventricles in patients with first episode of schizophrenia". World Congress on Psychiatric Genetics XV. New York City, USA. 2007

Crespo-Facorro B "Treatment of first episode psychosis: effectiveness and safety of antipsychotics". The early phase of psychosis: Research and Treatment. London, UK. November 2007

González-Blanch C et al. "Do concepts based on psychotic symptoms predict neurocognitive outcome in recent-onset schizophrenia?". International Congress on Schizophrenia Research. Colorado Springs, USA. March-April 2007

Rodríguez-Sánchez JM et al. "Association between cognition and clinical symptoms in first episode psychosis". International Congress on Schizophrenia Research. Colorado Springs, USA. March-April 2007

Sánchez-Cubillo I et al. "Comparison between the effect of typical and atypical antipsychotics on cognition: a three-month follow-up in first episodes of psychosis". International Congress on Schizophrenia Research. Colorado Springs, USA. March-April 2007

Roiz-Santiañez R et al. "Reduced thalamic volume in drug-naïve first episode schizophrenia patients: Correlations with cognitive variables". International Congress on Schizophrenia Research. Colorado Springs, USA. March-April 2007

Pérez-Iglesias R et al. "One year randomized clinical trial of haloperidol, olanzapine or risperidone to determine weight gain pattern in a drug-naïve population of first episode psychotic patients". International Congress on Schizophrenia Research. Colorado Springs, USA. March-April 2007

Pelayo-Terán JM et al. "Age of onset and duration of untreated psychosis in first episode psychosis: Interaction effects between cannabis and COMT". International Congress on Schizophrenia Research. Colorado Springs, USA. March-April 2007

Simal T et al. "Insight y adherencia farmacológica: factores determinantes en las recaídas de los primeros episodios de psicosis". XI Congreso Nacional de Psiquiatría. Santiago de Compostela, Spain. September 2007

Pelayo-Terán JM et al. "Interacción entre COMT y consumo de cannabis: Modulación de edad de inicio y DUP en primeros episodios de psicosis". XI Congreso Nacional de Psiquiatría. Santiago de Compostela, Spain. September 2007

Rueda I et al. "Recaídas en primeros episodios psicóticos durante los 3 primeros años". XI Congreso Nacional de Psiquiatría. Santiago de Compostela, Spain. September 2007

Pardo G et al. "Incidencia de esquizofrenia y factores de riesgo epidemiológicos asociados a Cantabria: PAFIP 2001-2005". XI Congreso Nacional de Psiquiatría. Santiago de Compostela, Spain. September 2007

Sanz A et al. "Función cognitiva y predicción de recaídas en una población de primeros episodios psicóticos". XI Congreso Nacional de Psiquiatría. Santiago de Compostela, Spain. September 2007

Martín-Muñoz V et al. "Estrés familiar en las psicosis iniciales: efectos de un grupo psicoeducativo". V World Congress of Behavioural & Cognitive Therapies. Barcelona, Spain. July 2007

González-Blanch C et al. "Lack of association between clinical and cognitive change in first-episode psychosis: The first six weeks of treatment". International Neuropsychological Society Mid-year Meeting. Bilbao, Spain. July 2007

Carral-Fernández L et al. "Unimpaired orbitofrontal function in first-episode schizophrenia: Evidence from the object alternation task". International Neuropsychological Society Mid-year Meeting. Bilbao, Spain. July 2007

Duarte-Armolea A et al. "Neuropsychological effects of cannabis abuse in first episode psychosis patients". International Neuropsychological Society Mid-year Meeting. Bilbao, Spain. July 2007

PUBLISHED ARTICLES IN INTERNATIONAL JOURNALS

González-Blanch C et al. (2007) "Cognitive dimensions in first-episode schizophrenia spectrum disorders". *Journal of Psychiatric Research* (2007); 41(11): 968-977

Crespo-Facorro B et al. (2007) "Caudate nucleus volume and its clinical and cognitive correlations in first episode schizophrenia". *Schizophrenia Research* (2007). In press (accepted on December 19 of 2006)

Crespo-Facorro B et al. (2007) "Neuropsychological functioning and brain structure in schizophrenia". *International Review of Psychiatry* (2007); 19(4): 325-336

Crespo-Facorro B et al. (2007) "Predictors of acute treatment response in patients with a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables". *Journal of Psychiatric Research* (2007); 41(8): 659-666

Crespo-Facorro B et al. (2007) "Low-activity allele of Catechol-O-Methyltransferase (COMT) is associated with increased lateral ventricles in patients with first episode non-affective psychosis". *Progress in Neuro-Psychopharmacology & Biological Psychiatry* (2007); 31(7):1514-1518

Crespo-Facorro B et al. (2007) "Reduced thalamic volume in first-episode non-affective psychosis: Correlations with clinical variables, symptomatology and cognitive functioning". *NeuroImage* (2007); 35(4): 1613-1623

González-Blanch C et al. (2008) "Preserved Orbitofrontal Function in First-Episode Schizophrenia. Further Evidence From the Object Alternation Paradigm". *The Journal of Nervous and Mental Disease* (2008); 196(1): 67-70

González-Blanch C et al. (2007) "Pretreatment predictors of cognitive deficits in early psychosis". *Psychological Medicine* (2007) Oct 9; 1-10

Mata I et al. (2007) "Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis". *Psychological Medicine* (2007); 38: 1-10

Pelayo-Terán JM et al. (2007) "Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Characteristics in First Episode Non-Affective Psychosis". *American Journal of Medical Genetics Part B, Neuropsychiatric Genetics* (2007). In press 1-7

Pérez-Iglesias R et al. (2007) "A 12-Week Randomized Clinical Trial to Evaluate Metabolic Changes in Drug-Naïve, First-Episode Psychosis Patients Treated with Haloperidol, Olanzapine or Risperidone". *Journal of Clinical Psychiatry* (2007); 68(11): 1733-1740

Pérez-Iglesias R et al. (2007) "Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population". *Schizophrenia Research* (2007). In press (accepted on October 18, 2007). DOI:10.1016/j.schres.2007.10.022

Roiz-Santiáñez R et al. (2008) "Interleukin-1 receptor antagonist genotype and brain morphometry in first-episode non-affective psychosis". *Psychiatry Research Neuroimaging* (2007). In press (accepted on October 10, 2007). OI:10.1016/j.pscychresns.2007.10.001

Rodríguez- Sánchez JM et al. (2008) "Cognitive functioning and negative symptoms in first episode schizophrenia: Different patterns of correlates". *Neurotox Res* (in press)

González-Blanch C et al. (2008) "Lack of association between clinical and cognitive change in first-episode psychosis: the first six weeks of treatment". *Can J Psychiatry* (in press)

2007-2011 SENYFOUNDATION III CALL FOR COORDINATED PROJECTS IN SCHIZOPHRENIA RESEARCH1

SENYFoundation promoted the III Call for Coordinated Projects in Schizophrenia Research 2007 with a grant of up to US\$ 300,000 for a single project.

SENYFoundation's Board Committee, following the recommendations of the two scientific committees involved in the announcement, decided on July 23, 2007 to award the financial help to the project "Monoaminergic neurotransmission in prefrontal cortex: Target for augmentation strategies in schizophrenia", the winning project led by Dr Francesc Artigas (from the Institut D'Investigacions Biomèdiques de Barcelona, CSIC-IDIBAPS). Researchers from the Hospital Clínic de Barcelona and the Hospital Sant Joan de Déu are collaborating in the project.

KEY ELEMENTS OF THE WINNING PROJECT

Title: *Monoaminergic neurotransmission in prefrontal cortex: Target for augmentation strategies in schizophrenia*

Principal Investigator:
Dr Francesc Artigas

Centre: Institut d'Investigacions Biomèdiques de Barcelona, CSIC-IDIBAPS - Fundació Clínic per a la Recerca Biomèdica, Spain

Amount granted: 235.440 €

Researchers in the Project:

- Dr Miquel Bernardo, Hospital Clínic de Barcelona
- Dr Eduard Vieta, Hospital Clínic de Barcelona
- Dr Josep M. Haro, Sant Joan de Déu, SSM

The activities organised during the first few months of the project have been as follows:

1. Intracerebral microdialysis studies on rats on dopamine (DA) differential regulation in prefrontal cortex and accumbens nucleus (mesocortical and mesolimbic routes, respectively).
2. Electrophysiological studies on rats to evaluate the effect of the agonist 5-HT_{2A} DOI and the agonist 5-HT_{1A} 8-OH-DPAT on low-frequency cortical oscillations.
3. Electrophysiological studies on rats for finalising the technique for registering cmap cortical potentials.

4. Learning behavioral techniques for work memory studies and cognitive flexibility (one year stay by Dr. Anna Castañé at Prof. Trevor W. Robbins' laboratory; Cambridge Univ. on a FIS contract)
5. Presentation of project results and related subjects in two international conferences.
6. Methodology standardization for the clinical study.

ORAL PRESENTATIONS

Masana M, Artigas F, Bortolozzi A (2007)
 "Regulation of extracellular dopamine levels in mesocortical and mesolimbic pathways":
 Billboard in the conference "Common neuro-circuits underlying common symptoms in psychiatric disorders". Huelva, Spain 2007

PUBLISHED ARTICLES IN INTERNATIONAL JOURNALS

Celada P, Puig MV, Díaz-Mataix L, Artigas F
 "The hallucinogen DOI reduces low frequency oscillations in rat prefrontal cortex. Reversal by antipsychotic drugs". *Biol Psychiatry* (provisionally accepted, pending minor revisions)

Artigas F "The prefrontal cortex: A target for antipsychotic drugs". *Acta Psychiat Scand* (revised article as solicited by the editor)

SENYFoundation would like to thank the following doctors for their scientific advice:

National

Dr Jordi Camí, Parc de Recerca Biomèdica de Barcelona.

Dr Jesús A. García Sevilla, Institut Universitari d'Investigació Biomèdica de Palma de Mallorca.

International

Dr E. Fuller Torrey, The Stanley Medical Research Institute, USA.

In May, Mr J. Masià, President of the **SENYFoundation** and Dr J. Bigorra, Director of the Clinical Foundation for Biomedical Research,

travelled to Washington DC to visit Dr E. Fuller Torrey, Executive Director of the Stanley Medical Research Institute and to bring up to date their knowledge of current research in schizophrenia.

COMMUNICATIONS AND DISSEMINATION

ARCHIVE CENTER

At **SENYFoundation** we continue to work towards expanding our bibliographic resources with more books and magazines, also stocking our library with Spanish doctoral theses on schizophrenia. Currently the library has approximately 330 books and the following specialized magazines:

- *Schizophrenia Bulletin* (from vol. 17, no. 2, 1991 to the 1st quarter of 2004, renewed on 2005 to present date)
- *Schizophrenia Research* (from vol. 47, no. 1, 2001 to present date)
- *Archives of General Psychiatry* (from vol. 54, no. 3, 1997 to present date)
- *The Barcelona School of Medicine journal of psychiatry* (vol. 29, no. 6, 2002 to present date)
- *Prostaglandins Leukotrienes and Essential Fatty Acids* (vol. 70 no. 1, 2, 3, 5, 6, vol. 71 no. 1, 2, 3, 4, 5,6 and vol.72 no.1 and 2)
- *Anales de Psiquiatría* (vol. 21 no.1 2004, to present date)



Document Centre resources

To date, doctoral theses provided by their authors number 48.

1. El curs de les hospitalitzacions en els malalts que pateixen esquizofrènia. Anàlisi de tres registres de casos psiquiàtrics. Josep Maria Haro Abad. Barcelona, 1995
2. Expansió de trinucleòtids repetits del tipus CAG en l'esquizofrènia. Lourdes Martorell Bonet. Reus, 1998
3. Características fenotípicas de personalidad y neuropsicológicas en padres no afectados de pacientes esquizofrénicos. Beatriz Caparrós Caparrós. Girona, 1999
4. Características de la fosforilación de la proteína asociada a los microtúbulos 2 en su región rica en prolinas. Carlos Sánchez Martín. Madrid, 1997
5. Efectivitat d'una intervenció psicosocial en un Grup de pacients psicòtics crònics. Núria Farriols i Hernando. Barcelona, 2001
6. Riesgo en psicopatología en hijos de padres psicóticos. Juan Manuel Blanco López. Barcelona, 1993
7. Psicofisiología de los procesos cognitivos en las esquizofrenias. José Ignacio Robles Sánchez. Madrid, 1994
8. L'orientació terapèutica familiar en l'esquizofrènia: evolució de familiars i pacients. Carles Ballús Creus. Barcelona, 1996
9. Esquizofrenia, cronicidad y calidad de vida. Rafael Touriño González. Las Palmas de Gran Canaria, 2001
10. Estudio de los mecanismos inhibitorios de la atención visuoespacial: inhibición de retorno en tareas de interferencia visual. Ana Belén Vivas Navarro. Almería, 1999
11. Estudio del flujo sanguíneo cerebral en pacientes con esquizofrenia y controles sanos mediante PET-H215O a través de un paradigma de atención auditiva. Pilar López García. Pamplona, 2001
12. La rehabilitació neuropsicològica del pacient esquizofrènic. Rafael Penadés. Barcelona, 2002
13. Evaluación de la eficacia de un programa de entrenamiento en habilidades sociales para personas que padecen esquizofrenia. Roser Cirici. Barcelona, 2000
14. Prenatal suffering and genetic variability as causative factors of schizophrenia and schizophrenia spectrum disorders phenotype. Araceli Rosa i de la Cruz. Barcelona, 2002
15. Estudi del rendiment cognitiu dels pacients en el primer episodi d'esquizofrènia i de la seva evolució després d'un any de tractament de la malaltia. Maite Garolera i Freixa. Barcelona, 2003
16. Genetic variation in serotonergic system genes: vulnerability for major depression and pharmacogenetics of response to SSRI antidepressants. Barbara Arias Sampérez. Barcelona, 2003
17. El concepto de esquizofrenia en los autores españoles a través de las publicaciones psiquiátricas españolas (1939-1975). Fernando Dualde Beltrán. Valencia, 2004
18. Teràpia facilitada per animals de companyia en pacients psicòtics greument deteriorats. Antoni Mayol Pou. Palma, 2002
19. Rehabilitación cognitiva en esquizofrenia: Aplicación del APT (Attention Process Training). Beatriz López Luengo. Madrid, 2000
20. Las necesidades de las personas con esquizofrenia que viven en la comunidad. Susana Ochoa. Barcelona, 2004
21. La percepción de señales sociales en la esquizofrenia y el trastorno bipolar. Bárbara Echevarría. Deusto, 2004
22. Factors de risc genètic per a l'esquizofrènia: Anàlisi de la variabilitat genètica de receptors dopaminèrgics (DRD2 i DRD3) i serotoninèrgics (HTR2A i HTR2C). Mar Fatjó-Vilas. Barcelona, 2004
23. Neuroimagen estructural en primeros episodios psicóticos de comienzo en la infancia y adolescencia. Dolores M. Moreno. Madrid, 2004
24. Segmentación estadística de imágenes de resonancia magnética. Joan D. Gispert, 2003
25. Evolución de los síntomas negativos en psicosis nunca tratada. Francisco Javier Manzanera. Murcia, 2003

26. Anàlisi de la evolució de los déficits cognitivos en la esquizofrenia: un estudio neuropsicológico transversal. Igor Bombín González. Deusto, 2004
27. Neurobiología de los trastornos del pensamiento en la esquizofrenia: un análisis electrofisiológico del sistema semántico. Francisco Muñoz Muñoz. Madrid, 2003
28. Funció serotoninèrgica i resposta terapèutica en pacients amb esquizofrènia: la corba plasmàtica de prolactina mitjançant estimulació amb m-clorofenilpiperacina. Joan Salvà i Coll. Barcelona, 2006
29. Esquizofrenia y síndrome metabólico: Análisis de la prevalencia. Tomás Sánchez-Araña Moreno. Las Palmas de Gran Canaria, 2006
30. Aplicación del 123I-IBZM SPECT al estudio de las fases tempranas de la psicosis: implicaciones pronósticas y terapéuticas. Iluminada Corripio Collado. Barcelona, 2006
31. Estudio longitudinal de la percepción de la calidad de vida en pacientes con esquizofrenia que viven en la comunidad a lo largo de 7 años. Janina Mónica Carlson Aburto. Barcelona, 2007
32. Farmacoepidemiología y Farmacogenética de la esquizofrenia. Macarena Cáceres León. Extremadura, 2006
33. La emoción expresada en una muestra costarricense de pacientes esquizofrénicos. Sílvia Sánchez Oller. Barcelona, 2001
34. Bases neuroanatómicas y neurofuncionales del trastorno de atención en la esquizofrenia: estudio mediante resonancia magnética. Pilar Salgado Pineda. Barcelona, 2002
35. Avaluació dels efectes neuroconductuals de l'exposició a manganès en animals d'experimentació. Influència de l'estrès. Margarita Torrente. Rovira i Virgili, 2002
36. Investigación y desarrollo de abaperidona, nuevo antipsicótico 5HT_{2A/D2} y alfa₁-adrenérgico. Modelos *in vitro* e *in vivo* predictivos de eficacia y efectos adversos. Marta Príncipe. Barcelona, 2004
37. Control recíproco entre la corteza prefrontal y los núcleos del rafe. Papel de los receptores de serotonina. M. Victoria Puig. Barcelona, 2004
38. Acció de fàrmacs antipsicòtics sobre el circuit escorça prefrontal-nuclis del rafe. Mercè Amargós i Bosch. Barcelona, 2005
39. Personalidad esquizotípica y marcadores cognitivos. Correlatos cognitivos en la esquizotipia psicométrica. Esther Álvarez López. Barcelona, 2005
40. Esquizofrenia, habilidades sociales y funcionamiento social. Carlos Cuevas Yust. Sevilla, 2003 <http://fondosdigitales.us.es>
41. Polimorfismos en los receptores dopaminérgicos D₂ y D₃, y en el transportador de dopamina DAT, y su relación con el riesgo de síntomas extrapiramidales por antipsicóticos y con el riesgo de esquizofrenia" Mònica Aparici Virgili. Barcelona, 2006
42. Alucinaciones auditivas en la esquizofrenia: Estudio del metabolismo remisión clínica y tras estimulación auditivo-lingüística. Mireia Font Planells. Barcelona, 2005
43. La expresión plástica como alternativa de comunicación en pacientes esquizofrénicos: arte terapia y esquizofrenia. María Vassiliadou Yiannaka. Madrid, 2001 <http://www.ucm.es/eprints/4856/>
44. Intervención psicoterapéutica en la fase inicial de la esquizofrenia: diseño y desarrollo del programa PIPE. Carol Palma Sevillano. Barcelona, 2007
45. Anàlisi mutacional i estudi d'associació del gen receptor domini discoidina 1 (ddr1) en l'esquizofrènia. Carmen Virgos Matilla. Tarragona, 2004
46. Estudi de l'eficàcia d'un programa d'entrenament cognitiu de les funcions executives amb persones que pateixen esquizofrènia. Gemma Espel Trias. Barcelona, 2007
47. Estudi de les determinacions d'àcid homovanílic en plasma i proves atencionals com a factors pronòstic a l'esquizofrènia. Inmaculada Baeza Pertegaz. Barcelona, 2006
48. Impulsividad y obsesividad en el trastorno obsesivo-compulsivo: cambios en los patrones de respuesta hormonal tras estimulación serotoninérgica y de flujo sanguíneo cerebral en relación con diversas variables clínicas. Benedicto Crespo-Facorro. Madrid, 2003 <http://www.ucm.es/eprints/2891/>

The following theses may be accessed directly at www.tdx.cesca.es:

SENYFoundation WEB PAGE

The **SENYFoundation** continues to offer all professionals and interested individuals information of its research activities in schizophrenia and serious mental disorders through its web page, www.senyfundacio.org.



SENYFoundation Home Web Page

The main services offered by the web are:

- Current information about the **SENYFoundation** and its research, training and educational activities.
- Virtual library. The document base can be accessed through our web site and reservations of the required bibliographic resources can be made. The **SENYFoundation** offers this service free to the whole of Spain with the aim of facilitating access to useful information for research and training purposes.
- Documental resources. It includes links which may be useful when searching for information about psychiatry, and links with medical evidence based Data Bases, pharmacology, etc.
- Material published by the **SENYFoundation**. Over recent years, the **SENYFoundation** has participated in the creation and publication of a variety of books and documents. In this section, all of the **SENYFoundation**

materials can be seen and our Working Papers downloaded.

- Links of interest. A list of links to web pages of interest to professionals and families is available. These links are classified in four extensive sections: Research, Scientific Societies, Awards and Grants, and Families.

DISSEMINATION OF COURSES AND GRANTS

Occasionally, national and international courses, conferences and scholarships offered by different institutions are circulated by email.


PRESENCE OF SENYFoundation IN PUBLIC ACTS

SENYFoundation has been present in the following symposiums and conferences:

- 15th Symposium on Bipolar Disorders. Comorbidity and its Treatment. Barcelona, February 2, 2007.
- 15th European Congress of Psychiatry. Madrid, March 17-21, 2007.
- 4th Annual Meeting of the AEP-Neuroimaging Section: Harnessing the power of multimodal integration in neuroimaging. Santander, May 3-4 2007.
- World Congress of Behavioural and Cognitive Therapies. Barcelona, July 11-14 2007.
- European Conference on Mental Health: Join forces across Europe for prevention and promotion in mental health. Barcelona, September 13-15, 2007.
- Jornada: Apropant la recerca en salut mental a la societat. [Conference: Bringing Mental Health Research To Society] Barcelona, September 20, 2007.
- Cicle de conferències. Preparant el futur ara: Intervenció en situacions de crisi en salut mental. [Lecture series: Preparing Now for the Future: Intervention in a Mental Health Crisis Situation] Barcelona, November of 2007.
- II International Symposium on Psychiatric Therapy. Problem Solving in Clinical Practice: Unipolar Depression. Barcelona, November 29-30, 2007.



SENYFoundation has jointly circulated a CD of the "Estudio bibliométrico sobre la investigación en esquizofrenia en España (1999-2004): Productividad, Impacto y Colaboración (2ª Edición)" [Bibliometric study on schizophrenia research in Spain (1999-2004):



Productivity, Impact and Collaboration (2nd Edition)] and Dr Torrey's book "Superar la Esquizofrenia (2ª Edición)" [second Spanish edition of "Surviving Schizophrenia (5th Edition)"] published by Editorial Planeta.



Despite the complicated nature of the illness, research into schizophrenia is not a vain, useless activity. Improved research on a particular disease at a particular place simultaneously yields improved clinical care at that place. Research prevents clinicians from falling into a daily routine, making them more likely not only to improve their treatments, but also to more rapidly integrate the treatments and research taking place throughout the scientific world.

Research does not belong only to big industry. Very frequently, individuals or teams with only limited financial

support make important scientific discoveries that solve old problems. Our country is well equipped with the right people who have the potential to become important, perhaps decisive, researchers on any particular disease. The history of our medicine is full of such examples.

Mr Jordi Masia
President of the SENYFoundation



FINANCIAL RESOURCES. SOURCE OF RESEARCH FUNDS

FAMILY AND FRIENDS

Although taking care of mentally ill patients at home is hard and onerous, it is the most important help. But those who are in a position to do something more for others and for future generations should, without question, support research into this devastating disorder. This is something that we are convinced will, in the long term, turn out to be most gratifying.

COMPANIES AND CORPORATIONS – CSR *

Some large companies and corporations in our country have been sensitive to our project and have provided us with significant support. They have fulfilled the new vision for companies known as Corporate Social Responsibility - CSR. Their intelligent and generous gesture is much appreciated.

CSR is a new business perspective that is gaining force among the most successful companies both here and around the world. It is a new business culture that has abandoned the reductionist view which was previously prevalent and represents a redefinition of the social function of business.

CSR does not imply in any way a change, or antagonism toward the nature of market economy. On the contrary, we realise that good practice in corporate responsibility constitutes an indicator of the management and governing quality of companies. It is clear that business results improve when companies are able to achieve trusting relationships with their interest groups. The latest generation of good governance codes published by CNMV (Comisión Nacional de Mercado de Valores - National Commission of Market Values) recommends the inclusion of CSR into the current objectives considered by management boards.

The adoption of CSR filters into the relationships with stakeholders; in other words, to the

companies' own employees, clients and suppliers. This also shapes the companies' own culture and often has the additional beneficial effect of giving it substantial competitive advantages.

CSR, as a new business perspective, has attracted attention not only at Harvard and other leading business schools in the US, but also here. Important business schools, which are incidentally extremely well placed in the international rankings such as IESE and ESADE, are treating this subject in a preferential way.

You, the patients and family, must realise the enormous potential that you represent for the large corporations and companies of your country as a special interest group and should protect your interests accordingly.

* Extract from our President's intervention at the Conference "Aproant la recerca en salut mental a la societat" (Bringing Research on Mental Health to Society). Celebrated on September 20, 2007, on the occasion of the World Mental Health Day.

Sources:

2007 Report on Corporate Social Responsibility in Spain Responsabilidad. The new challenges of the CSR – Fundación Alternativas. Talk and book presentation, Cercle d'Economia, Barcelona 12/07/07.

Talk. Juan Ramon Quintás, President of CECA at the Cercle Financer de Barcelona 23/07/07.

IESE Global Alumni Reunion, Barcelona 27-28/09/07.

ESADE Business School's Institute for Social Innovation, Director Ignasi Carreras. Círculo Ecuestre, Barcelona 30/10/07.



SENYFOUNDATION COLLABORATION WITH OTHER ORGANIZATIONS

- AATRM (Agència d'Avaluació de Tecnologia i Recerca Mèdiques)
CAHTA (Catalan Agency for Health Technology Assessment and Research)
- Centres Assistencials Dr. Emili Mira
Dr Emili Mira health care centres
- Clínica Universitària de Navarra
Clinical University of Navarra
- Consorci Hospitalari Parc Taulí
Parc Taulí Corporation
- Consorci Sanitari del Maresme, Hospital de Mataró
Mataró Hospital Consortium
- Editorial Planeta
Planeta Publishers
- Federació Catalana de Familiars de Malalts Mentals
Catalan Federation of Family Associations for Mental Health
- Fundació Abertis
Abertis Foundation (previously called Castellet de Foix Foundation)
- Fundació ADANA
ADANA Foundation
- Fundación Argibide
Argibide Foundation (Pamplona)
- Fundació Catalana per a la Recerca
Catalan Foundation for Research
- Fundación Cuatrecasas
Cuatrecasas Foundation
- Fundació "la Caixa"
"la Caixa" Foundation
- Fundación M^a Francisca de Roviralta
M^a Francisca de Roviralta Foundation
- Fundació Clínic per a la Recerca Biomèdica
Clinic Foundation for Biomedical Research
- Fundació Sant Joan de Déu
Sant Joan de Déu Foundation
- Fundació Parc Taulí
Parc Taulí Foundation
- Generalitat de Catalunya
(Catalan government)
- Hospital Clínic de Barcelona
Clinical Hospital of Barcelona
- Hospital Universitario Marqués de Valdecilla, Santander
University Hospital Marqués de Valdecilla, Santander
- IMIM (Institut Municipal d'Investigació Mèdica)
Municipal Insitute for Medical Research
- Institut d'Assistència Sanitària (IAS), Girona
Institute for Health Care Assistance (IAS), Girona
- Institut d'Investigacions Biomèdiques de Barcelona, CSIC-IDIBAPS
CSIC-IDIBAPS
- Institut Pere Mata de Reus
Pere Mata de Reus Institute
- Sant Joan de Déu, Serveis de Salut Mental
Sant Joan de Déu, Mental Health Services
- Stanley Medical Research Institute
- Universitat Autònoma de Barcelona
Autonomous University of Barcelona
- Universitat de Barcelona
University of Barcelona



SPONSORING ENTITIES

abertis



 Agència d'Avaluació de Tecnologia i Recerca Mèdiques



Fundación
CUATRECASAS



FUNDACION PRIVADA
VILA CASAS




MANOIN 64


 **Planeta**

TORRES



senyfundació

Schizophrenia Research Foundation

C/ Diputació, 238 át. 7
08007 BARCELONA
Tel. (34) 93 302 30 10
Fax. (34) 93 301 33 58

www.senyfundacio.org
seny@senyfundacio.org